Song Hong-Jun, Xue Yan-Li, Qiu Zhong-Ling, Luo Quan-Yong
Department of Nuclear Medicine, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai, China.
Nucl Med Commun. 2013 Dec;34(12):1196-203. doi: 10.1097/MNM.0000000000000001.
The loss of 131I uptake ability in metastases from differentiated thyroid carcinoma (DTC) is becoming a major obstacle in radioiodine treatment. However, there is no effective way to screen for 131I uptake ability in metastases. The identification of differentially expressed proteins by serum proteomics may contribute to our understanding of the mechanisms underlying the dedifferentiation of DTC.
Serum samples were obtained from papillary thyroid carcinoma patients with non-131I-avid lung metastases and 131I-avid lung metastases. Differential protein analysis was performed using two-dimensional gel electrophoresis. Candidate protein spots showing differences in expression between the two groups were identified by means of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and were validated by western blotting.
We found that afamin is downregulated in the serum of papillary thyroid carcinoma patients with non-131I-avid lung metastases.
Afamin may be a potential serum biomarker for early screening of 131I uptake ability in DTC metastases and could therefore be of value in guiding radioiodine treatment decisions.
分化型甲状腺癌（DTC）转移灶丧失¹³¹I摄取能力正成为放射性碘治疗的主要障碍。然而，目前尚无有效的方法来筛查转移灶的¹³¹I摄取能力。通过血清蛋白质组学鉴定差异表达蛋白可能有助于我们理解DTC去分化的潜在机制。
收集甲状腺乳头状癌伴非¹³¹I摄取性肺转移和¹³¹I摄取性肺转移患者的血清样本。采用二维凝胶电泳进行差异蛋白分析。通过基质辅助激光解吸/电离飞行时间质谱鉴定两组间表达存在差异的候选蛋白点，并通过蛋白质印迹法进行验证。
我们发现，在甲状腺乳头状癌伴非¹³¹I摄取性肺转移患者的血清中，载脂蛋白A-F表达下调。
载脂蛋白A-F可能是早期筛查DTC转移灶¹³¹I摄取能力的潜在血清生物标志物，因此在指导放射性碘治疗决策方面可能具有价值。
